Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock are in focus ahead of a major drug pricing deal with the Trump administration. Read more here.

President Trump, Lilly, and Novo Nordisk agree to lower prices of GLP-1 weight-loss drugs for Medicare, Medicaid, and cash payers.

The Trump administration is reportedly expected to announce a deal with Eli Lilly and Novo Nordisk on Thursday that would ...

U.S. President Donald Trump, Eli Lilly and Novo Nordisk unveiled a deal on Thursday to slash the prices of popular GLP-1 ...

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit ...

Announced new clinical trial agreement with Pfizer to evaluate palazestrant in combination withatirmociclib in ER+/HER2- metastatic breast ...

Thank you, operator. Hello, and welcome, everyone. Today's earnings call will be led by Dr. Samantha Du, Zai Lab's Founder, CEO and Chairperson. She will be joined by Josh Smiley, President and Chief ...

The deal, which includes Eli Lilly and Novo Nordisk, will slash prices for Medicare and Medicaid programme recipients.

Pfizer's CEO thinks his company will make big waves in the weight loss market. Eli Lilly does have a strong hold on the ...

Pfizer on Thursday closed its up to $10 billion acquisition of Metsera after winning shareholder approval, gaining a foothold ...

ADVANCING MOST-FAVORED-NATION (MFN) PRICING: Today, President Donald J. Trump announced the latest in a series of the most significant actions ever taken by our Federal government to lower ...